Host Defense: Are we immune by chance?
The sooner the immune system launches, the greater the chances the host has of survival.
- Princeton University, United States
- Vanderbilt University, United States
Literature and cinema abound with stories of chance encounters that lead to life-changing events. Likewise, in meteorology, the flap of a butterfly’s wing can, in theory, lead to the formation of a tornado thousands of miles away, due to the cascading effects of randomness and stochastic variation. However, the role of chance in immunology has received scant attention.
Our understanding of immune defense has greatly improved over the decades, but one central question still preoccupies scientists: why do people respond to infection in such different ways, when the right response can make the difference between life and death? Several factors are thought to influence immunity, including age, gender or genes. Now, in eLife, David Duneau, Nicolas Buchon and colleagues at Cornell University and the University of Toulouse 3 report that random variations in how long it takes the host’s immune system to react could also play a role in determining if the host can survive an infection (Duneau et al., 2017).
The researchers suggest that whether a host lives or dies is partly a matter of a lucky start. To test this idea, Duneau et al. studied how genetically identical fruit flies, raised in the same environment, responded to a variety of pathogens. The bacteria caused two possible outcomes – death or chronic infection – with significant differences in the fate of individual flies. Moreover, these differences were independent of the amount of pathogen, the age of the host, and the genetic background of both the host and the pathogen.
Duneau et al. developed a mathematical synopsis of their results, which showed that timing was a crucial factor: the sooner the immune system reacted to a potential threat, the higher the chances of survival were. If the immune system responded too late, the bacteria continued to grow until the fly died (Figure 1). Thus, even subtle variations during the early stages of an immune response can lead to stark differences in the chances of dying.
Figure 1
A conceptual framework to explain why variations in immune activation lead to different disease outcomes.
In a simple model (top), microbes (N) grow exponentially at rate μ, while each immune cell or effector molecule (I) can kill a microbe at rate γ. The number of immune cells or molecules depends on the rate λ, which in turn depends on a number of factors such as the level of standing immunity, the time taken to activate the immune response (bottom left), and the maximum capacity of the system to produce immune components. The interaction between a given type of microbe and the immune system can be characterised by a map (bottom right) that plots μN – γI as a function of I (horizontal axis) and N (vertical axis). If the growth rate of microbes exceeds the killing capacity of the immune system (μN > γI), the microbes grow exponentially throughout the infection (solid line; red region). If the growth rates become equal (μN = γI), the outcome is a persistent, 'set-point' level of chronic infection (long dashes; white region). If the growth rate of the immune response outpaces that of microbes (μN < γI), the infection will clear up (short dashes; blue) – this was, however, rarely observed in the fruit flies. Duneau et al. suggest that if the number of microbes reaches a certain level (Ntip), the host will become incapable of producing a sufficient immune response to control the microbes. In this case, the bacteria will continue to grow until the host is dead.
The idea that random variations can have such potent effects may seem surprising and appear to contradict our current knowledge of immunological pathways in both insects and mammals, which are often described as deterministic (e.g., Janeway and Medzhitov, 2002; Lemaitre and Hoffmann, 2007). Qualitatively speaking, they may well be deterministic (in the sense that event A triggers expression of B, which in turn triggers pathogen-killing mechanism C). However, the devil is in the quantitative detail, as we can expect randomness in every step.
For example, the launch of an immune response can sometimes be predicted by mass action, because collisions have to take place between the pathogens and the cells of the immune system (e.g., Sykulev et al., 1995): the stronger the pathogen attack, the higher the immune reaction, on average. Nevertheless, how rapidly immune cells react will vary by host (Frank, 2002), partly because of variation in the rate at which immune cells patrol through the body (e.g., Lee et al., 2012). But pure chance can also influence the likelihood and strength of a response, particularly in hosts exposed to very few pathogens (e.g., Ben-Ami et al., 2010). Subtle variation in the initial density, reactivity and efficacy of immune cells is therefore likely to translate into stochasticity in the induced response.
Duneau et al. provide insight into the role of such chance in host-pathogen interactions. The survival of a fly was linked to the ability of the pathogen to multiply before the fly's defense kicked in. Once the immune system got the upper hand, the pathogen density went down to a certain persistent value that the researchers called the ‘set-point’ (Figure 1). The sooner the immune system succeeded, the greater the chances of survival. However, if the bacterial burden outstripped the immune system, the fly eventually died.
This interplay between random variations and determinism in the early stages of the immune response may well explain other life or death outcomes following changes in diet or repeated exposure to pathogens (e.g., Howick and Lazzaro, 2014; Tate et al., 2017). More generally, the work of Duneau et al. furthers our understanding of the evolutionary processes that drive host-parasite interactions, including natural selection for rapid and accurate inducible defenses (Frank, 2002; Tollrian and Harvell, 1999). We look forward to further work that will help to uncover the mechanisms underlying these fascinating findings. But for now, the role of chance in driving or constraining such processes remains a frontier of science.
References
-
Immune response to parasitic attack: evolution of a pulsed characterJournal of Theoretical Biology 219:281–290.https://doi.org/10.1006/jtbi.2002.3122
-
Innate immune recognitionAnnual Review of Immunology 20:197–216.https://doi.org/10.1146/annurev.immunol.20.083001.084359
-
The host defense of Drosophila melanogasterAnnual Review of Immunology 25:697–743.https://doi.org/10.1146/annurev.immunol.25.022106.141615
-
The within-host dynamics of infection in trans-generationally primed flour beetlesMolecular Ecology 26:3794–3807.https://doi.org/10.1111/mec.14088
-
BookThe Ecology and Evolution of Inducible DefensesPrinceton: Princeton University Press.
Article and author information
Author details
Publication history
- Version of Record published: November 27, 2017 (version 1)
Copyright
© 2017, Graham et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,817
- views
-
- 179
- downloads
-
- 4
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Host Defense: Are we immune by chance?
eLife 6:e32783.
https://doi.org/10.7554/eLife.32783
Further reading
-
- Microbiology and Infectious Disease
In the Firmicutes phylum, GpsB is a membrane associated protein that coordinates peptidoglycan synthesis with cell growth and division. Although GpsB has been studied in several bacteria, the structure, function, and interactome of Staphylococcus aureus GpsB is largely uncharacterized. To address this knowledge gap, we solved the crystal structure of the N-terminal domain of S. aureus GpsB, which adopts an atypical, asymmetric dimer, and demonstrates major conformational flexibility that can be mapped to a hinge region formed by a three-residue insertion exclusive to Staphylococci. When this three-residue insertion is excised, its thermal stability increases, and the mutant no longer produces a previously reported lethal phenotype when overexpressed in Bacillus subtilis. In S. aureus, we show that these hinge mutants are less functional and speculate that the conformational flexibility imparted by the hinge region may serve as a dynamic switch to finetune the function of the GpsB complex and/or to promote interaction with its various partners. Furthermore, we provide the first biochemical, biophysical, and crystallographic evidence that the N-terminal domain of GpsB binds not only PBP4, but also FtsZ, through a conserved recognition motif located on their C-termini, thus coupling peptidoglycan synthesis to cell division. Taken together, the unique structure of S. aureus GpsB and its direct interaction with FtsZ/PBP4 provide deeper insight into the central role of GpsB in S. aureus cell division.
-
- Microbiology and Infectious Disease
Mechanisms by which Mycobacterium tuberculosis (Mtb) evades pathogen recognition receptor activation during infection may offer insights for the development of improved tuberculosis (TB) vaccines. Whilst Mtb elicits NOD-2 activation through host recognition of its peptidoglycan-derived muramyl dipeptide (MDP), it masks the endogenous NOD-1 ligand through amidation of glutamate at the second position in peptidoglycan side-chains. As the current BCG vaccine is derived from pathogenic mycobacteria, a similar situation prevails. To alleviate this masking ability and to potentially improve efficacy of the BCG vaccine, we used CRISPRi to inhibit expression of the essential enzyme pair, MurT-GatD, implicated in amidation of peptidoglycan side-chains. We demonstrate that depletion of these enzymes results in reduced growth, cell wall defects, increased susceptibility to antibiotics, altered spatial localization of new peptidoglycan and increased NOD-1 expression in macrophages. In cell culture experiments, training of a human monocyte cell line with this recombinant BCG yielded improved control of Mtb growth. In the murine model of TB infection, we demonstrate that depletion of MurT-GatD in BCG, which is expected to unmask the D-glutamate diaminopimelate (iE-DAP) NOD-1 ligand, yields superior prevention of TB disease compared to the standard BCG vaccine. In vitro and in vivo experiments in this study demonstrate the feasibility of gene regulation platforms such as CRISPRi to alter antigen presentation in BCG in a bespoke manner that tunes immunity towards more effective protection against TB disease.
